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Abstract: Hepatitis C virus (HCV) infects over 130 million people worldwide and is a 
major cause of liver disease. No vaccine is available. Novel specific drugs for HCV are 
urgently required, since the standard-of-care treatment of pegylated interferon combined 
with ribavirin is poorly tolerated and cures less than half of the treated patients. Promising, 
effective direct-acting drugs currently in the clinic have been described for three of the ten 
potential HCV target proteins: NS3/NS4A protease, NS5B polymerase and NS5A, a 
regulatory phosphoprotein. We here present core, the viral capsid protein, as another 
attractive, non-enzymatic target, against which a new class of anti-HCV drugs can be 
raised. Core plays a major role in the virion’s formation, and interacts with several cellular 
proteins, some of which are involved in host defense mechanisms against the virus. This 
most conserved of all HCV proteins requires oligomerization to function as the organizer 
of viral particle assembly. Using core dimerization as the basis of transfer-of-energy 
screening assays, peptides and small molecules were identified which not only inhibit core-
core interaction, but also block viral production in cell culture. Initial chemical 
optimization resulted in compounds active in single digit micromolar concentrations. Core 
inhibitors could be used in combination with other HCV drugs in order to provide novel 
treatments of Hepatitis C.  
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1. Introduction  
Hepatitis C virus (HCV) infects over 130 million people world-wide [1-2]. It is a single stranded 
positive RNA enveloped virus which belongs to the hepacivirus genus in the flaviviridae family [3-6]. 
The 9.6 kilobase long viral RNA encodes a polyprotein of approximately 3,010 amino acid residues 
[7]. The HCV polyprotein is co- and post-translationally processed into ten individual components by 
host cell signal peptidases and viral peptidases [8]. All ten proteins are essential for viral infectivity, 
and most are endowed with several functions [7,9].  
HCV is the main cause of chronic liver disease in humans. There is no anti-HCV vaccine. The only 
effective 48-week treatment currently available combines pegylated interferon-alpha and ribavirin, but 
the overall success rate is less than 50%, depending on the viral genotype and strain [10]. Its use is 
plagued with side effects and poor compliance [11]. Small molecule HCV-specific inhibitors that 
target directly the individual viral proteins NS3/NS4A serine protease, and RNA-dependent RNA 
NS5B polymerase are in advanced stages of clinical development. [12-15] 
Here we discuss core, the HCV capsid protein, as a novel non-enzymatic target for anti-HCV drug 
discovery likely to yield agents with a resistance profile different from inhibitors of HCV enzymes. 
We review core’s role in the assembly of the virion, and we describe assays to identify, select and 
optimize peptides and small molecule inhibitors of core dimerization and viral production. We discuss 
the use of such inhibitors to probe and control core’s activity in HCV. 
2. Core as a target protein for anti-HCV drug discovery 
Viral capsid proteins have been proposed previously as targets for anti-viral drugs, based on the fact 
that they are essential for virus assembly, are highly conserved even in viruses which mutate 
extensively, and self-assemble in well-controlled conditions easy to assay in vitro [16]. Despite these 
advantages, only Hepatitis B and Human Immunodeficiency Viruses have so far provided good 
examples that support the validity of the strategy [17-19]. What makes HCV core an especially 
attractive target, in addition to its dual role in viral infection and persistence, is the fact that it is the 
most conserved of all HCV proteins, across the 6 major genotypes, and that it is the least variable of 
the ten HCV proteins in variant viruses emerging constantly in patients [10]. This exceptional level of 
conservation reflects its essential role and suggests that its use as a therapeutic target across all 
genotypes is unlikely to be affected by mutations causing resistance, thus providing a profile quite 
distinct from other direct-acting drugs. While mutations in core influencing HCV’s response to 
interferon have been studied recently in connection with treatment with a new anti-protease inhibitor 
[20], such substitutions remain exceedingly rare, when compared to the multiple mutations emerging 
in NS3 and NS5 enzymes, mostly used so far as targets for anti-HCV drug discovery [21-22]. Finally, 
adding to these advantages, biochemically functional C-terminally truncated versions of core are easy Viruses 2010, 2                  
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to prepare and purify, and readily dimerize and oligomerize in vitro in absence or presence of RNA 
[23]. 
3. Core’s role in HCV’s life cycle 
3.1. Core interactions with other HCV proteins  
Core is essential for nucleocapsid assembly and interacts with several other viral proteins, namely 
the E1 glycoproteins [24], p7 and NS2 [25], NS3 [26] and NS5A [27]. These interactions were 
confirmed by immuno-staining followed by confocal microscopy which revealed co-localization of 
core with NS5A and NS3 on lipid droplets [26,28] and were supported by yeast-two hybrid analyses 
[29-31] and co-precipitation data [28,32]. Molecular genetics provided additional evidence for core-NS 
protein interactions: spontaneous mutations in p7 and NS2 rescued production of virus mutated in core 
[25]; site-directed mutagenesis, alanine scanning [25], and other methods led to the identification of 
several residues in both core and NS5A presumably involved in the co-localization of the two proteins, 
although direct evidence for in vitro binding of NS5A to core has proven to be difficult to obtain  
[32-33]. 
3.2. Core’s role in assembly 
Core, the capsid protein, plays a central role in the HCV life cycle: it is essential for lipid droplet 
mobilization [34-35], recruitment of HCV replicase proteins, nucleocapsid formation, and assembly 
and release of viral particles from infected cells [36-37].  
The sequence of events leading to core-orchestrated HCV particle assembly is schematically 
depicted in Figure 1, and can be described to progress from left to right as follows: after translation, 
the HCV polyprotein is directed to the Endoplasmic Reticulum (“ER”) by a signal peptide sequence 
situated at the C-terminal end of core, immediately adjacent to the E1 glycoprotein. Two successive 
cleavages, first by a cellular signal peptidase [38] then by a cellular signal peptide peptidase [39-40] 
result respectively in release from the polyprotein and migration of mature, probably dimerized 
/oligomerized core, to the surface of LD’s [41]. Core then recruits, most if not all non-structural HCV 
proteins from the ER: NS3 [26], NS5A [28,32], NS5B and possibly p7 and NS2 [42-43], which 
together constitute the replicase complex, responsible for RNA replication (Figure 1). At the surface of 
LD’s, core also interacts with a number of non-HCV proteins (not represented in Figure 1) , namely 
those involved in Very Low Density Lipoproteins (VLDL) biogenesis such as ApoE, ApoB and 
Microsomal Transfer Protein [44-45]. Newly synthesized HCV RNA is transferred from the replicase 
complex to core, and the resulting nucleocapsid is associated into lipid-encapsulated particles, together 
with E1 and E2 glycoproteins (Figure 1). The stoechiometry, the sequence and timing of these events 
are still debated. 
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Figure 1. A schematic (left to right) model for assembly of the HCV particle. Core-
directed assembly takes place at the surface of lipid droplets (“LD”). Core, originally made 
as a 191 residue protein, migrates from the endoplasmic reticulum to the surface of LD’s 
after removal of the C-terminal 14 residues by a host signal peptide peptidase [38-39,46]. 
Core oligomers recruit to the LD surface NS3, NS5A, NS5B, and possibly other HCV 
replicase proteins implicated in the synthesis of HCV RNA, including p7 and NS2 
[4,27,47]. HCV nucleocapsids resulting from the binding of RNA to core are then 
associated via unknown processes with HCV glycoproteins E1 and E2 and processed 
through the VLDL assembly pathway [27,48] (not shown here), to yield lipid 
encapsulation, resulting in budding of viral particles [49]. Whether the replicase complex 
as such interacts with core before or after RNA is made, and whether RNA binds to core 
dimer / oligomer on LD’s is not yet known, nor is the stoechiometry between core, RNA 
and the E1, E2 glycoproteins (modified from [28]). 
 
 
4. Core’s structure and function 
Core contains a number of amino-acid residues essential for assembly and release of the viral 
particle [50], and for interaction with other HCV proteins, such as the E1 glycoprotein and replicase 
proteins NS3 [26] and NS5A [51]. These various roles have been assigned to different parts of the 
protein (Figure 2).The N-terminal basic domain, up to residue 117 (“ D1”) binds and promotes 
dimerization of the viral RNA [52], leading to formation of viral nucleocapsid [53-54]. Recent analysis 
of core mutants in this domain revealed that D1 also contains a sequence crucial for core envelopment 
by endosomal membranes [41]. The generally more hydrophobic C-terminal domains “D2”, and “D3”, 
interact with the Lipid Droplets, with the E1 and E2 glycoproteins, and with several host proteins Viruses 2010, 2                  
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themselves involved in lipid transport [27,47,55]. The 177 residue mature core [46,56] is translocated 
from the endoplasmic reticulum to the lipid droplet surface [57]: the transmembrane C-terminal core 
peptide remains in the ER, where it serves as the E1 glycoprotein signal sequence [39,58]. Core’s role 
as a powerful chaperone, and as an inducer of dimerization of newly-made HCV RNA has been well 
recognized [53]. It’s essential function is increasingly appreciated as an organizer of particle assembly 
(Figure 1) as well as mediator of host-pathogen interactions.  
Figure 2. Structural and Functional domains of the HCV core protein. Core is made as a 
191 residue long polypeptide, and is trimmed by a signal peptide peptidase, down to a  
177-residue mature protein [46,57]. Various synthetic C-terminally truncated versions of 
recombinant core have been used in order to characterize its functional domains: core82 
[59], core106 [23] , core122, “D1” [55], core169 [55], and core177, “D2” [39,57]. 
 
 
Dimerization and most interactions with intracellular proteins are mostly mediated by the N-
terminal region of core, whereas binding to cellular membranes [60], to LD’s and to glycoprotein E1 
have been mapped to the more hydrophobic C terminus [54]. The N-terminal half of core contains 
many of the residues essential for homotypic interaction and nucleocapsid formation [61] [29,62-63]. 
In a cell-free system for core synthesis, the residues critical for capsid formation were all located in the 
first 68 positions of core [64] and core 1 to 82 was designated as the minimal domain for nucleocapsid 
assembly [61,65].  Alanine scanning revealed numerous core residues essential for infectious virus 
production, including a significant number in the first 120 positions of the protein [25]. The C-terminal 
region comprised between residues 118 and 169 is required for proper folding of the whole core 
protein and preservation of interactions not observed with D1 [55]. For instance, mutations of residues 
at position 130, 138 or 143 all abrogate association with LD’s and virus production [34,66]. Core’s D2 
C-terminal half thus harbors several sites that are essential for the protein’s roles in HCV’s life cycle, 
e.g. for binding and attracting other HCV proteins to LD’s. In addition, core’s C-terminal is involved 
in mechanisms of viral persistence, oncogenesis [67] and steatosis [68].  
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5. Assays for analyzing core function: 
To improve the understanding of core oligomerization and the role of dimerization in interaction 
with other proteins and nucleocapsid formation, various biochemical assays were developed:  
a. Assays for Nucleocapsid formation 
Several groups have proposed assays to evaluate the function of core based on its capacity to 
oligomerize or form nucleocapsid-like structures in the presence of RNA [59,61,64-65]. An assay for 
measuring the turbidity resulting from the addition of RNA to core served to define core-derived 
peptides essential for this complex formation [61]. Unexpectedly, these peptides did not originate from 
the core homotypic region, between residues 82-102, thought to be responsible for core dimerization. 
Furthermore, the nucleocapsid assay did not distinguish between RNA from HCV or from a variety of 
other sources, including tRNA.  
b. Core dimerization 
In order to physico-chemically characterize core dimerization and identify identify high affinity 
inhibitors, three types of assays were designed and developed: Enzyme Linked Immuno Sero Assay 
(“ELISA”), Time Resolved-Fluorescence Resonance Energy Transfer (“TR-FRET”) and Amplified 
Luminescent Proximity Homogeneous Assay (AlphaScreen) [23,69-70].  
To avoid complications due to limited solubility of mature (ie: D1+D2) core protein, these assays 
were developed using a D1-like dimerizing portion of core, comprising the first 106 residues, and 
further designated as “core106”. 
1.   For developing a sandwich ELISA, GST-tagged core106 domain was adsorbed on microplates 
coated with glutathione, and a horse-radish peroxidase goat anti-mouse antibody was used to 
demonstrate binding of anti-Flag antibody to Flag-tagged core106 itself bound to   
GST-core106 (Figure 3). This result demonstrated hetero-dimerization of the two fusion 
proteins. Free GST, Flag peptide or untagged core106 each displaced specific binding to 
background levels. [23].  
2.    The ELISA was useful to qualitatively demonstrate the interaction when using alternately 
tagged core106 fusion proteins, but the need for multiple washes hampered a precise analysis 
of the interaction, and precluded its use for screening of large compound libraries. For this 
purpose, a TR-FRET homogenous assay was developed, using the same GST-and Flag-tagged 
core106 proteins (Figure 4) [23,69]. Fluorophore-labeled antibodies against the GST and Flag 
tags allowed the authors to quantitatively measure the formation of dimers and oligomers of 
core106. The TR-FRET was particularly well adapted for robotized high-throughput screening 
in 384- and 1,536-well microplates of large small compound libraries [69]. The typical signal 
to background ratio shown in Figure 4 left, was rather low, although the inhibitory signal 
(Figure 4 right) was quite adequate for identifying “primary hit” inhibitors [69]. 
3.   To develop a more sensitive assay for precise dose-response analyses, an AlphaScreen assay 
was developed, as a secondary format for monitoring core106 dimerization, but using donor 
and acceptor beads coated respectively with Glutathione or anti-Flag antibodies respectively, 
resulting in assays with at least 50-fold signal to background ratios (Figure 5) [23,70]. Again, Viruses 2010, 2                  
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untagged core106 domain was used as a reference inhibitor, with an IC50 of 89 nM [23]. While 
AlphaScreen beads are not easily handled by most robotic suites found in high-throughput 
screening laboratories, and sometimes vary in day-to-day stability, they provided a remarkably 
sensitive format for following chemical optimization of primary hit compounds first identified 
in large scale screening [70]. 
Figure 3. A scheme and data for sandwich ELISA showing dimerization of core106. 
Core106 was tagged with either a “GST” tag or a “Flag” tag. A sandwich ELISA was 
performed by adsorbing GST-core106 on a Glutathione-coated plate and different 
concentrations of Flag-core106 were added to the plate. Mouse-anti-Flag antibody, horse 
radish peroxidase tagged anti-mouse IgG, and Ultra TMB-HRP, a horse radish peroxidase 
substrate were utilized for the visualization of GST-core106 and Flag-core106 complex. 
 
 
6. Inhibitors of core dimerization  
6.1. Inhibition of core106 and core169 dimerization by peptides 
Protein-protein interactions can generally be inhibited by peptides derived from either one of the 
two partners [72].To identify such inhibitor peptides of core dimerization, fourteen 18-residue peptides 
derived from core were evaluated in energy transfer TR-FRET and AlphaScreen assays validated by 
dose-response analyses [23,69-70]. Two peptides SL173 and SL174, overlapping by 11 residues, 
inhibited core dimerization by 68 and 63% respectively. A third peptide, SL175, corresponding to 
SL174 C-terminally truncated by three residues, inhibited core dimerization by 50%. These three 
inhibitory peptides share the sequence:  Viruses 2010, 2                  
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              -Gly-Trp-Ala-Gly-Trp-Leu-Leu-Ser-Pro-Arg-Gly- 
which corresponds to a “hot spot” defined as a small subset of residues involved in protein-protein 
interactions that contributed most of the free energy of binding between the two protein partners [72].  
Peptide SL200, containing only this 11-residue sequence, inhibited core dimerization by 30-40%, 
but was not soluble enough to reach concentrations that would yield higher inhibition rates [23]. The 
Ser residue within SL200 corresponds to Ser99 which was earlier reported to be essential for core 
function in the whole virus: its substitution by an Ala residue strongly affects HCV viability [25], and 
reduces fourfold its ability to inhibit core dimerization [23]. The SL200 sequence is conserved among 
genotypes 1a, 1b 2a and 3, and is situated within the 82-102 homotypic domain of core defined earlier 
[73]. A dose-response analysis of peptide SL175 yielded an IC50 of 21.9 µM. SL571, a control peptide 
which contains the reverse sequence of SL175 displayed no effect on core dimerization [23]. 
Figure 4. A scheme and data for TR-FRET assay for monitoring dimerization of core106. 
Core106 was tagged with either a “GST” tag or a “Flag” tag. Europium cryptate-tagged 
anti-GST and Allophycocyanin (XL-665)-tagged anti-Flag antibodies were used to 
measure the core-core interaction. Since no known inhibitor of core dimerization was 
available, untagged core106 domain was used as a reference inhibitor. Top panel – Scheme 
for core106 TR-FRET assay. Bottom left panel- Dose response of GST-core106 and   
Flag-core106 dimerization. Bottom right panel – Inhibition of GST-core106 and Flag-
core106 dimerization by reference inhibitor core106. The transfer of fluorescence was 
measured as a ratio of (signal at 665nm / signal at 620nm) *10,000. 
 
 
Direct and specific interaction of SL175 with core was demonstrated by two physico-chemical 
methods. For Fluorescence Polarization (“FP”) studies, SL175 was conjugated to fluorophore 
Alexa488 and a dose-response analysis yielded a Kd of 1.9 µM for the binding of the coupled peptide Viruses 2010, 2                  
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to core106. Displacement of the A488 peptide by free peptide yielded an IC50 of 18.7 µM, in close 
agreement with the value of 21.9 µM obtained by AlphaScreen. Surface Plasmon Resonance (“SPR”) 
analysis done with core169, yielded an apparent Kd of 7.2 µM [23].  
Cross-linking studies performed as described [23], confirmed that SL175 binds directly to core106 
monomers and dimers [74]. Control peptide SL571 displayed no evidence of binding to either core 
truncated protein, in any of the FP, SPR or cross-linking studies [23].  
6.2. Inhibitors of core dimerization by organic molecules 
The TR-FRET and AlphaScreen assays described in section 5 were used to identify organic 
molecule inhibitors of core dimerization in a library of 2,240 compounds from the Center for Chemical 
Methodology and Library Development of Boston University [69-70]. Included in this collection were 
representatives of a small molecule, 132-membered library of tetracyclic heterocyclic compounds. 
Compounds with this general chemotype were originally viewed as desirable due to their structural 
similarity to the Aspidosperma alkaloids, well known for their broad range of biological activities  
[75-76]. Furthermore, their production was relatively straightforward and easily amenable to parallel 
synthesis protocols [77].  
Figure 5. Left panel – Scheme for core106 AlphaScreen assay. This assay is based on the 
use of photoactive donor and acceptor beads that recognize specific tags on interacting 
proteins. An interaction between proteins brings the beads in close proximity. This triggers 
a cascade of chemical reactions which produces a greatly amplified signal. When excited, a 
photosensitizer in the donor bead converts ambient oxygen to a more excited singlet state 
which then reacts with a chemiluminescent molecule in the acceptor bead which further 
activates fluorophores contained within the same bead to emit light [71]. Right panel- 
Assay confirming interaction of GST-core106 and Flag-core106 and inhibition of the 
interaction by untagged core106 [23,69].  
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The best “primary hit” compound present in this indoline alkaloid-type library, designated as SL201 
(MW 513 daltons, structure in Figure 6 top), was shown to block core106-core106 and core106-
core169 dimerization by over 90%, nearly as efficiently as core106 itself, used as a 100% control 
inhibitor. A dose–response analysis yielded an IC50 equal to 9 µM [69].  
Using SL201’s structure as prototype, a second generation library of 82 members was prepared, 
exploiting chemistry similar to that used in preparing SL 201. The scaffold of this library varied the  
D-ring of the initial scaffold, featuring a -lactam with a diversified lactam nitrogen (Figure 6 bottom). 
Forty-eight of these new analogues were screened, and those capable of inhibiting over 50% of the 
GST-core106/Flag-core106 interaction were further investigated by dose-response analysis yielding 
IC50 values ranging from 20 down to 1.4 µM. SL209 was the most promising compound in that second 
series, and its structure is also presented in Figure 6 [70]. The activities of the members of this second 
generation library established that the D-ring ester group of the first generation was not essential for 
the activity of SL 201 [69-70].  
Figure 6. Structure and activity of small molecule inhibitors of HCV core dimerization and 
virus production [69-70]. Top: half maximal inhibitory concentration (IC50) values 
determined in the core dimerization assay. The half maximal cytotoxicity concentration 
(CC50) values (see section 7) were determined using uninfected hepatoma cells. The T1 
and T2 half maximal effective concentration (EC50) values were obtained using the same 
cells but infected with HCV 2a J6/JFH1 virus at two different passages [23,69-70]. 
Bottom: chemical structures of SL201 and SL209 [69].  
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7. Inhibition of HCV production by inhibitors of core dimerization  
Huh-7.5 hepatoma cells were electroporated with RNA from HCV and the 72-hour supernatant was 
used as a source of infectious virus. This supernatant was combined with peptides or compounds 
identified as inhibitors of core dimerization [23,70]. Two stages of infection were studied: T1, 
corresponding to the initial 72-hour culture of naïve cells infected in the presence of the inhibitor, and 
T2, corresponding to the second 72-hour passage through naïve cells. HCV RNA detected in T1 results 
from actual viral infection and replication. HCV RNA detected in T2 results from infectious virus 
secreted in T1 and replicated in freshly infected naïve cells. 
After determining that inhibitors of core dimerization were not toxic for Huh-7.5 hepatoma cells, 
their capacity to inhibit production of HCV by in vitro infected cells was evaluated [23,69-70], using 
the HCV 2a J6/JFH-1 culture system [78-80]. 
7.1. Peptide inhibitors of HCV 
Peptides SL173, 174 and 175 displayed no significant toxicity towards uninfected cells, when used 
below 100 µM concentrations [23]. When added in 10 to 20 µM concentrations to HCV-infected cells, 
these peptides reduced production of the virus, as determined both by limited dilution Tissue Culture 
Infectious Dose – 50% (TCID-50) studies [23] and by Real Time RT-PCR measurement of HCV 
RNA[69-70].  
For peptide SL173, this result was indirectly confirmed by Cheng et al. [81] who showed by direct 
assay of the 441 HCV polyprotein-derived peptides added one by one to HCV-infected cells, that a 
core-derived peptide identical to SL173, reduced respectively by a factor of 9 and 11 the production of 
HCV RNA in 24-hour and 72-hour culture [81]. 
7.2. Small compound inhibitors of HCV 
Compounds SL201 and SL209 which did not display toxicity up to 320 µM and 100 µM 
respectively (Figure 6) were evaluated for inhibition of HCV production in culture at two stages, T1 
and T2. HCV RNA was quantified by Real-Time RT-PCR. Compounds SL201 and SL209 reduced 
HCV RNA production respectively by about two logs with EC50 of 8.8 µM for T1 and 8.1 for T2, and 
2.3 µM for T1 and 3.2 µM for T2 (Figure 6) [69-70]. 
7.3. Mode of action of inhibitors 
7.3.1. Peptides 
To investigate their mode of action, inhibitor peptides were added before, together and after 
infection with HCV. Reduction of infectivity was only observed after infection was established [23], 
suggesting that the peptides had no effect on entry or replication, but might act on assembly. This 
conclusion would fit with the fact that the peptides were originally identified as inhibitors of core 
dimerization. No evidence was reported however to demonstrate that the peptides were actually able to 
penetrate the HCV-infected cells. Another 18-mer peptide [8] derived from the same NIH library of 
441 HCV polyprotein-derived peptides, was detected inside HCV-infected cells, after coupling with a Viruses 2010, 2                  
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dansyl moiety, which served as an epitope for anti-dansyl antibodies [81]. Although that peptide had a 
different sequence and very different biological properties from SL173 and SL174, its similar size 
suggests that 18-mer peptides can indeed penetrate Huh-7.5 HCV infected cells.  
7.3.2. Small organic molecule inhibitors 
The mode of action by which organic molecules SL201 and SL209 reduce HCV infectivity has not 
yet been established. It was shown however that the compounds had no effect on production of HCV 
replicons, confirming that they do not affect HCV RNA replication [69-70]. The inhibitors appeared to 
act on virus production by cells three days after electroporation with RNA from HCV: this experiment 
was actually done for SL201 on RNA from HCV of two distinct strains: J6/JFH-1 of genotype 2a  
[78-80] and CG of genotype 1b [82]. The inhibitor acted equally well on the 2a virus released in the 
supernatant of cells infected by T1 or T2 [23,69]. These results suggest that SL201 affect neither virus 
entry into the cells, nor replication of RNA, supporting the hypothesis that this inhibitor of core 
dimerization / oligomerization might act on virion assembly. 
8. Future developments 
Core plays an important role in various steps of the HCV infectious cycle including nucleocapsid 
assembly and recruitment of other HCV proteins to the site of viral production. The precise 
understanding of the importance of core oligomerization and of its interactions with other HCV and 
cellular proteins will provide unique insights in its role in the viral life cycle. Peptides and small 
molecule disruptors of core dimerization, which act as potent inhibitors of HCV, constitute unique 
novel molecular probes for HCV function and complement current molecular genetics approaches for 
the study the HCV life cycle. Importantly, these studies might also impact studies of other Flaviviridae 
viruses for which coupling between virion assembly and genome replication has been suggested to 
result from interaction between core and non-structural proteins. Furthermore, future drugs acting on 
core as a target might potentially provide an important breakthrough for novel combination treatments 
of Hepatitis C. 
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